ManufacturingWith a $70 million expansion in Massachusetts, AbbVie plans...
Manufacturing

With a $70 million expansion in Massachusetts, AbbVie plans the next phase of its US investment adventure

Editotial Team
By Editotial Team

-

951
0

No content provided.

e8ca33a26f7037921e92de08cb2a519d8f9a37c9966383abf07edbf18b55cb25?s=150&d=mp&r=g
+ posts
Previous article
Rocket abandons its attempt to obtain FDA approval for bone marrow gene therapy
Next article
Aerska Launches with $21 Million to Develop RNAi Medicines for Neurological Diseases
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team

Latest news

Insights

Remote Monitoring in Clinical Trials

Executive Summary Clinical trials are becoming increasingly decentralized, data-driven, and patient-centric. As sponsors conduct studies across more locations and seek...
Insights

The Rise of In Silico Clinical Trials

Executive Summary Clinical trials remain one of the most important and expensive stages of drug development. They provide essential evidence...
Clinical

Novo Reports Late-Stage Semaglutide Trial Results in Children With Obesity

Novo Nordisk said on Monday that its late-stage STEP Young trial found that 40.4% of children aged 6 to...

Must read

Commercial

Commercial Excellence Summit Brings Together Leading Minds to Solve Critical Commercial Problems

This week is set to be a pivotal one...
Commercial

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you

Manufacturing

ArsenalBio Lays Off 99 Employees and Shifts Focus to In Vivo CAR-T Programs

Arsenal Biosciences (ArsenalBio) is reducing its workforce by 99...
Editorial Team -
Manufacturing

Aura Biosciences Refocuses on Ocular Oncology Programs and Cuts Workforce by 20%

Aura Biosciences is restructuring its operations under recently appointed...
Editorial Team -
Manufacturing

Ensoma Restructures Operations to Focus on EN-374 for X-Linked Chronic Granulomatous Disease

Boston-based biotechnology company Ensoma has carried out another organizational...
Editorial Team -
Manufacturing

Novo Nordisk Sues Eli Lilly Over GLP-1 Drug Advertising Claims

Novo Nordisk has filed a lawsuit against Eli Lilly...
Editorial Team -